The expression and ratio of CD20 and CD59 molecules vary substantially in non-Hodgkin’s lymphoma and chronic lymphocytic leukemia patient-derived cell lines [42,43,44] and it will be extremely interesting to discover, to what extent the novel anti-CD20/CD59 construct can enhance CDC effect of RX for such diverse spectrum of cells. This evidence concerns the gene CD59 and B-cell chronic lymphocytic leukemia.